Search - tctmd.com

Displaying 141 - 160 of 363

Sort: Relevancy | Date

No Attenuation in CVD Risk Reduction for Patients Treated to Very Low LDLs: FOURIER

News Conference News ESC 2021

No Attenuation in CVD Risk Reduction for Patients Treated to Very Low LDLs: FOURIER

Michael O'Riordan

September 02, 2021

Fixed-Dose Combo Therapy Slashes CVD Risk in Primary Prevention

News Conference News ESC 2021

Fixed-Dose Combo Therapy Slashes CVD Risk in Primary Prevention

Michael O'Riordan

August 31, 2021

2021 ESC/EACTS Valve Guidelines Unveil TAVI/SAVR Age Cutoffs and Earlier Care

News Conference News ESC 2021

2021 ESC/EACTS Valve Guidelines Unveil TAVI/SAVR Age Cutoffs and Earlier Care

August 31, 2021

‘Quadpill’ Beats Monotherapy at BP Lowering: QUARTET

News Conference News ESC 2021

‘Quadpill’ Beats Monotherapy at BP Lowering: QUARTET

August 31, 2021

STEP Trial Supports Lower BP Goal in Older Patients With Hypertension

News Conference News ESC 2021

STEP Trial Supports Lower BP Goal in Older Patients With Hypertension

August 30, 2021

IAMI: Influenza Vaccine Beneficial for Post-MI Patients

News Conference News ESC 2021

IAMI: Influenza Vaccine Beneficial for Post-MI Patients

Michael O'Riordan

August 30, 2021

LOOP and STROKESTOP: Impact of AF Screening May Hinge on Arrhythmia Burden

News Conference News ESC 2021

LOOP and STROKESTOP: Impact of AF Screening May Hinge on Arrhythmia Burden

August 29, 2021

Massive SSaSS Study Shows Switch to Salt Substitute Cuts Stroke, CVD

News Conference News ESC 2021

Massive SSaSS Study Shows Switch to Salt Substitute Cuts Stroke, CVD

Michael O'Riordan

August 29, 2021

Finerenone Reduces CV Outcomes in Patients With Early CKD, Diabetes: FIGARO-DKD

News Conference News ESC 2021

Finerenone Reduces CV Outcomes in Patients With Early CKD, Diabetes: FIGARO-DKD

Michael O'Riordan

August 28, 2021

ENVISAGE-TAVI AF: Edoxaban Disappoints in TAVI Setting

News Conference News ESC 2021

ENVISAGE-TAVI AF: Edoxaban Disappoints in TAVI Setting

August 28, 2021

MASTER DAPT: One Month's Enough in Patients at High Bleeding Risk

News Conference News ESC 2021

MASTER DAPT: One Month's Enough in Patients at High Bleeding Risk

August 28, 2021

EMPEROR-Preserved: Empagliflozin Improves Outcomes in HFpEF

News Conference News ESC 2021

EMPEROR-Preserved: Empagliflozin Improves Outcomes in HFpEF

August 27, 2021

GUIDE-HF: Pulmonary Artery Sensor May Help in Mild HF, but COVID-19 Muddies Water

News Conference News ESC 2021

GUIDE-HF: Pulmonary Artery Sensor May Help in Mild HF, but COVID-19 Muddies Water

August 27, 2021

Colchicine Lowers CVD Risk No Matter When Past ACS Occurred: LoDoCo2

News Daily News

Colchicine Lowers CVD Risk No Matter When Past ACS Occurred: LoDoCo2

Michael O'Riordan

August 26, 2021

USPSTF Lowers Screening Age for Diabetes, Prediabetes to 35 for Overweight Adults

News Daily News

USPSTF Lowers Screening Age for Diabetes, Prediabetes to 35 for Overweight Adults

August 25, 2021

Prasugrel Tops Ticagrelor in ACS Across the eGFR Spectrum: ISAR-REACT 5

News Conference News ESC 2021

Prasugrel Tops Ticagrelor in ACS Across the eGFR Spectrum: ISAR-REACT 5

August 24, 2021

Multivessel PCI May Be Less Suitable for Elderly STEMI Patients: NCDR Data

News Daily News

Multivessel PCI May Be Less Suitable for Elderly STEMI Patients: NCDR Data

August 20, 2021

ESC 2021: Trials, Guidelines, and Channel Surfing at This Year’s Virtual Congress

News Opinion Editor's Corner ESC 2021

ESC 2021: Trials, Guidelines, and Channel Surfing at This Year’s Virtual Congress

August 19, 2021

Short-term LAA Occlusion Outcomes Worse in Women

News Daily News

Short-term LAA Occlusion Outcomes Worse in Women

August 17, 2021

Endpoint Reporting in Medical Journals Needs to Be Revamped: Review

News Daily News

Endpoint Reporting in Medical Journals Needs to Be Revamped: Review

Michael O'Riordan

August 17, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.